TolerRx Completes $31 Million Series D Financing
TolerRx, a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies to treat patients with diseases of the immune system, announced the completion of its Series D financing. The funds raised will finance the company's clinical development programs and the continued advancement of its early product portfolio. Bear Stearns Health Innoventures (BSHI), a new investor to the company, led the $31 million round which included all existing investors along with other new investors. New investors include NIF Ventures and individual investors.